Dr. Neeraj Narula

Division of Gastroenterology

Neeraj Narula


Assistant Professor, Division of Gastroenterology, Department of Medicine

Staff Gastroenterologist, Hamilton Health Sciences






Education and Professional Standing

Dr. Neeraj Narula is an Assistant Professor of Medicine at McMaster University and Staff Gastroenterologist in Hamilton Health Sciences.  He joined the faculty in 2016. He trained to be a Chartered Accountant at the University of Waterloo and has worked at Ernst & Young and KPMG. He subsequently attended medical school at the University of Alberta. He completed internal medicine residency and gastroenterology fellowship training at McMaster University. He completed the Present-Levison advanced inflammatory bowel diseases (IBD) fellowship in Mount Sinai Medical Centre in New York, NY, in 2015. He subsequently pursued an MPH at Harvard TH Chan School of Public Health in Boston, MA.  He is certified in Internal Medicine and Gastroenterology by the Royal College of Physicians and Surgeons of Canada and the American Board of Internal Medicine. 

His clinical and academic interests are focused primarily in IBD, including Crohn’s disease and ulcerative colitis.  He also sees patients with general gastrointestinal disorders.  His research interests are predominantly in clinical epidemiology, nutrition, and interventional trials in inflammatory bowel diseases.  He has a special interest in alternative therapies for inflammatory bowel disease.  He conducted a randomized controlled trial examining the benefit of high-dose vitamin D3 for Crohn’s disease.  He is currently evaluating dietary interventions for Crohn’s disease and other alternative ways to modify the course of IBD (i.e. fecal microbiota transplantation).

Selected Publications

  1. Narula N, Kassam Z, Yuan Y, Colombel JF, Ponsoien C, Reinisch W, Moayyedi P. Systematic review and meta-analysis: fecal microbiota transplantation of active ulcerative colitis. Inflamm Bowel Dis 2017;23:1702-9.
  2. Narula N, Borges L, Steinhart AH, Colombel JF.  Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011.  Inflamm Bowel Dis 2017;23:868-74.
  3. Roda G, Narula N, Pinotti R, Skamnelos A, Katsanos K, Torres J, Colombel JF.  Systematic review and meta-analysis: proximal disease extension in limited ulcerative colitis. Aliment Pharmacol Ther 2017;45:1481-92.
  4. Colombel JF, Narula N, Peyrin-Biroulet L.  Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 2017;152:351-61.
  5. Hindryckx P, Novak G, Vande Casteele N, Laukens D, Narula N, Khanna R, Dulai P, Sandborn W, D’Haens G, Feagan B, Jairath V.  Review article: dose optimization of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther 2017;45:617-30.
  6. Narula N, Cooray M, Anglin R, Muqtadir Z, Narula A, Marshall J. Impact of high dose vitamin D3 supplementation in treatment of Crohn’s disease in remission: a randomized double-blind controlled Study. Dig Dis Sci 2017;62:448-55.
  7. Narula N, Steinhart AH. Preventative care in the IBD patient. CMAJ 2017;189:E243-4.
  8. Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, Eser A, Vogelsang H, Reinish W, Papay P. The efficacy and safety of infliximab and adalimumab in 362 Patients with anti-TNF naïve Crohn’s disease. Aliment Pharmacol Ther 2016;44:170-80.
  9. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF.  The real world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease – Results from the US VICTORY Consortium.  Am J Gastroenterol 2016;111:1147-55.